2024
Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology
Shinozuka K, Jerotic K, Mediano P, Zhao A, Preller K, Carhart-Harris R, Kringelbach M. Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology. Translational Psychiatry 2024, 14: 485. PMID: 39632810, PMCID: PMC11618481, DOI: 10.1038/s41398-024-03187-1.Peer-Reviewed Original ResearchConceptsFunctional connectivityBetween-network functional connectivityLevels of analysisWithin-network FCBetween-drug differencesMeta-analysesD2 receptorsPsychedelic effectsSerotonergic psychedelicsNeuroimaging resultsNeuropsychiatric disordersStates of consciousnessPsychedelicsNeural fingerprintsAltered statesNeuroimagingPsilocybinHigh dosesLSDSignificantly higher ratesMolecular pharmacologySystematic reviewAddictionDepressionPhenomenology
2022
TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor.
Jo U, Murai Y, Agama KK, Sun Y, Saha LK, Yang X, Arakawa Y, Gayle S, Jones K, Paralkar V, Sundaram RK, Van Doorn J, Vasquez JC, Bindra RS, Choi WS, Pommier Y. TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor. Molecular Cancer Therapeutics 2022, 21: 1090-1102. PMID: 35439320, PMCID: PMC9256811, DOI: 10.1158/1535-7163.mct-21-1000.Peer-Reviewed Original ResearchConceptsATR inhibitorsTop1 inhibitorsHomologous recombination deficiencyNovel molecular interactionApoptotic cell deathCancer cellsTop1 cleavage complexesAtaxia telangiectasiaCleavage complexesCell deathDNA damageHigher DNA damageMolecular interactionsDNA baseKinase inhibitorsI inhibitorMolecular pharmacologyMouse xenograftsTOP1Recombination deficiencyTopoisomerase I inhibitorInhibitorsTumor growthRad3Predictive biomarkers
2010
Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor
Meuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du-Cuny L, Herbst R, Jacoby JJ, Zhou LL, Ahad AM, Mash EA, Kirkpatrick DL, Powis G. Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor. Molecular Cancer Therapeutics 2010, 9: 706-717. PMID: 20197390, PMCID: PMC2837366, DOI: 10.1158/1535-7163.mct-09-0985.Peer-Reviewed Original ResearchMeSH Keywords3-Phosphoinositide-Dependent Protein KinasesAnimalsAntineoplastic AgentsFemaleHumansMiceMice, Inbred C57BLMice, NudeModels, BiologicalOncogene Protein v-aktProtein BindingProtein Interaction Domains and MotifsProtein Kinase InhibitorsProtein Serine-Threonine KinasesSulfonamidesThiadiazolesTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsAntitumor activityTumor xenograftsNon-small cell lung cancerMolecular pharmacologyCell lung cancerAdditive antitumor activityHuman tumor xenograftsPHT-427K-ras mutant tumorsVivo antitumor activityLung cancerSensitive tumorsPIK3CA mutationsBreast cancerImmunodeficient miceBlood chemistryMutant tumorsCombination studiesResistant cellsMinimal toxicityWeight lossTumorsCancerCancer cellsAkt inhibition
2005
Chapter 11 Molecular Pharmacology and the Treatment of Tourette's Syndrome and Attention Deficit-Hyperactivity Disorder
Arnsten A. Chapter 11 Molecular Pharmacology and the Treatment of Tourette's Syndrome and Attention Deficit-Hyperactivity Disorder. 2005, 183-iv. DOI: 10.1016/b978-012738903-5/50012-6.Peer-Reviewed Original ResearchAttention deficit hyperactivity disorderDeficit hyperactivity disorderPrefrontal cortexTourette syndromeTherapeutic actionUse of guanfacineΑ2-adrenoceptor agonistNeuropsychiatric symptomsAppropriate medicationNeuromodulatory effectsTourette patientsPostsynaptic sitesNeurochemical environmentNeuropsychiatric illnessBrain circuitsSyndromePFC regulationBasic neuroscienceMolecular pharmacologyMolecular targetsDisordersGuanfacinePatientsPFC functionTreatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply